AstraZeneca Halts Lung Cancer Drug Trial Following Heart Disease Trial Stoppage

POLICY WIRE — London, UK — Pharmaceutical giant AstraZeneca has terminated a clinical trial for its volrustomig lung cancer treatment. This decision comes a month after the company halted a trial for...

Editorial Desk

August 17, 2026 One Min Read

POLICY WIRE — London, UK — Pharmaceutical giant AstraZeneca has terminated a clinical trial for its volrustomig lung cancer treatment. This decision comes a month after the company halted a trial for a new heart disease medication.

The FTSE 100 firm announced the cessation of the volrustomig trial without providing specific reasons for the stoppage. This follows the earlier discontinuation of the heart disease drug trial, which similarly lacked detailed explanations.

AstraZeneca’s moves have raised questions within the medical and financial communities about the company’s ongoing research and development strategies. The company has yet to release further information on the outcomes or implications of these trial stoppages.

Reporting by Policy-Wire (PW)

📖 GET YOUR FREE COPY NOW OF POLICY WIRE DIGITAL MAGAZINE JULY 2026 EDITION

👉 READ & DOWNLOAD FREE MAGAZINE

Author

Editorial Desk

Policy Wire is your go-to editorial hub for insightful perspectives and informed analysis on pressing policy issues, both regionally and globally. Over the years, Policy Wire has collaborated with leading international news agencies—including AFP, AP, Reuters, and others—to provide fact-based reporting and nuanced commentary. With a commitment to clarity and credibility, we aim to bridge the gap between complex policy debates and public understanding, ensuring that our readers stay informed on the issues shaping the world today.